Acromegaly With Growth Hormone Excess Therapeutics
1. Palsonify patent expiration
Treatment: Treatment of adults with acromegaly who have hepatic impairment and an inadequate response to surgery and/or for whom surgery is not an option; Treatment of adults with acromegaly who had an inadequat...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11414397 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| US10597377 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| US10351547 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| US9896432 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| US10464918 | CRINETICS | NA |
Jan, 2039
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12208092 | CRINETICS | NA |
Mar, 2044
(18 years from now) | |
| US11957674 | CRINETICS | NA |
Sep, 2041
(15 years from now) | |
| US11266641 | CRINETICS | NA |
Sep, 2041
(15 years from now) | |
| US10875839 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2030 |
Drugs and Companies using PALTUSOTINE HYDROCHLORIDE ingredient
NCE-1 date: 25 September, 2029
Market Authorisation Date: 25 September, 2025
Dosage: TABLET
More Information on Dosage
PALSONIFY family patents
2. Somatuline Depot patent expiration
Treatment: Method of administering lanreotide acetate
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5595760 | IPSEN PHARMA | Sustained release of peptides from pharmaceutical compositions |
Mar, 2020
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2012 |
| New Dosing Schedule(D-131) | Mar 04, 2014 |
| Orphan Drug Exclusivity(ODE) | Aug 30, 2014 |
| New Indication(I-701) | Dec 19, 2017 |
| New Indication(I-754) | Sep 15, 2020 |
| Orphan Drug Exclusivity(ODE-82) | Dec 16, 2021 |
| Orphan Drug Exclusivity(ODE-156) | Sep 15, 2024 |
Drugs and Companies using LANREOTIDE ACETATE ingredient
NCE-1 date: 31 August, 2011
Market Authorisation Date: 30 August, 2007
Dosage: SOLUTION
More Information on Dosage
SOMATULINE DEPOT family patents